. Author manuscript; available in PMC: 2017 Nov 1.

Published in final edited form as: Urol Oncol. 2016 Sep 14;34(11):484.e19–484.e25. doi: 10.1016/j.urolonc.2016.05.033

Table 4. Multivariable Adjusted Comparison of BCG Connaught to BCG TICE: Patients with BCG maintenance.

		BCG Connaught (n=560) N, (%)	BCG Tice (n=205) N, (%)	Hazard Ratio (95% CI)	P value
Recurrence	No	319 (57.0)	136 (66.3)	0.66 (0.47 – 0.93)	0.019
Recurrence	Yes	241 (43.0)	69 (33.7)	0.66 (0.47 – 0.93)	0.019
Progression	No	466 (83.2)	176 (85.9)	0.79 (0.49 – 1.29)	0.35
Progression	Yes	94 (16.8)	29 (14.1)	0.79 (0.49 – 1.29)	0.35
Survival	Alive	423 (75.5)	167 (81.5)	0.72 (0.46 – 1.12)	0.14
Survival	Dead	137 (24.5)	38 (18.5)	0.72 (0.46 – 1.12)	0.14
Death Bladder Cancer	No	509 (89.9)	199 (97.1)	0.36 (0.14 – 0.92)	0.033
Death Bladder Cancer	Yes	51 (9.1)	6 (2.9)	0.36 (0.14 – 0.92)	0.033

HR > 1 favors Connaught, HR < 1 favors TICE